biopharma newsletters

Here are the latest deals. | Improving Adoption of Clinical Decision Support, HIT Perspectives Biopharma Insights (March 2014), Improving ePrescribing as an Important Tool for Managed Markets | The Top Ten Health IT Trends for 2014 | Accelerating ePrescribing for Controlled Substances. Why Care About the EHR Interoperability Brouhaha? The daily news briefing from the pharmaceutical industry. The daily news briefing from the packaging industry. A social After Covid-related delays that forced the FDA to delay its China-based inspections, Coherus BioSciences said today that its China-based partner Junshi Biosciences has now successfully Roche is planning to make some changes to its subsidiarys manufacturing network in California. The medical device industry's most comprehensive news and information delivered every month. Should Biopharma Prepare for a Future Parkinsons Wave? Last spring, GEN reported on companies applying emerging technologies that included Cas13-encoding mRNA, circular mRNA, programmable mRNA, and self-amplifying mRNA. The daily news briefing from the industry. Updated May 22, 2023 Deals Sponsored by Bio-Rad Private equity deal activity in the pharmaceutical industry in Europe decreased by 29% in Q1 2023, Whos acquiring who? What the 21st Century Cures Act Means for Health IT, HIT Perspectives Biopharma Insights (November 2016), Working Smarter, Not Harder: Helping Clinicians Optimize Use of EHRs, Computerized Order Sets Help Physicians Save Time and Improve Care, Electronic Dosing Instructions: Opportunities for Sales Teams, HIT Perspectives Biopharma Insights (September 2016), EHRs: A New Dissemination Tool for Patient Education Materials, Surescripts Issues its 2015 National Progress Report, Electronic Prior Authorization: Just What the Doctor Ordered (Almost), HIT Perspectives Biopharma Insights (June 2016), New Proposed Regulation Rebrands and Retools Meaningful Use, Cutting Through the Confusion Surrounding Electronic Formulary and Benefit Checks, Retail Medical Clinics: Untapped Resources for Patient Education, HIT Perspectives Biopharma Insights (April 2016), Integrating EHRs and PDMPs: How Vendors Can Get Ahead of the Curve, Alerting Prescribers for Biosimilar Substitution to Protect Patient Safety, HIT Perspectives Biopharma Insights (February 2016), Getting Doctors Ready for New Yorks War on Opioid Abuse, Meaningful Use: Not Entirely Gone but Certainly Not Forgotten, HIT Perspectives Biopharma Insights (November 2015), EHRS Can Expand the Quality and Scope of Physician Practices, Physicians Health, IT Priorities to Focus on ICD-10 and Meaningful Use. Pharma | Fierce Pharma The highlights go to news about decentralised clinical. The drugmaker cited testing delays and an evolving competitive landscape in its decision to discontinue development of its IL-23 inhibitor brazikumab. The agency will extend its review of Sareptas treatment byone month as it weighs limiting an initial OKto children with Duchenne aged 4 to 5 years old. Subscribe to BioPharma Dive for top news, trends & analysis, Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines, National Institute of Allergy and Infectious Diseases. Biopharma newsletter #71 November, 2022 Hi there, This month, I bring you some news about clinical trials, vaccines, EMWA conference, and more. The regulator denied an appeal of its decision to turn back vadadustat, but outlined a path forward for the company to resubmit an application without running another clinical trial. view sample | But companies have backed out. Its main thoroughfare is the wide avenue de Charles de Gaulle, which is a prolongation of the Champs-lyses and of the avenue de la Grande Arme. marketing communications. 2016. <>/ExtGState<>/XObject<>/Pattern<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 11 0 R 12 0 R] /MediaBox[ 0 0 595.32 842.04] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> Although primary data for the personalized cancer vaccine was expected in Q4 2022, the trials primary completion date is expected to be in September 2024. The Latest Deep Dive Biotech M&A is picking back up. Synthetic biology, or synbio, has disrupted industries as diverse as agriculture, food, and fashion, in addition to the biopharma industry. No longer dead or just hibernating, drugmakers return to heart medicines, European Parliament calls member states to action on antimicrobial resistance, Kyowa Kirin renews support for foundation that fulfills wishes for terminally ill adults, Amgen centers cancer patients voices in new YouTube series, Viatris targets ulcerative colitis in Japan with $10M agreement with Swedish pharma InDex, Whos spending and whos cutting from Big Pharmas $127B R&D budget? Growing Use of Oral Specialty Medications to Spur ePrescribing Adoption, Real-World Evidence Comes to Mainstream Health Care, HIT Perspectives Biopharma Insights (July 2014), Meaningful Use Learnings for Pharmaceutical Companies, Deciphering the Mystery of Population Health Management, Surescripts Stats Show ePrescribing Rounds Third Base, HIT Perspectives Biopharma Insights (April 2014), Guidelines and Best Practices: Ripe for an Assist from Managed Markets Teams, Improving Adoption of Clinical Decision Support, HIT Perspectives Biopharma Insights (March 2014), Improving ePrescribing as an Important Tool for Managed Markets, Accelerating ePrescribing for Controlled Substances. Stephen Hahns cancer-testing biotech hires a new CMO; Former Iovance exec named CEO of Obsidian, Vir enlists J&J vet to run business development; Gilead finds Kite successor to Christi Shaw, Astellas president jumps to a new Frontier; Grifols chairman named CEO, breaking family tradition, Maria Fardis ends a two-year CEO hiatus; More leadership turnover on the menu at Galapagos, 'Inspired' by Ipsen's mission, Sandra Silvestri joins as next CMO; Exicure's slide continues with CEO, CFO exits, FDA approves Pfizers RSV shot for older adults, teeing up a competitive $17B vaccine market, FDA's cancer chief weighs in on common chemo shortages report, Cancer association says national budget deal threatens research funding, CMS makes it official: Coverage for new Alzheimer's drugs once full approvals arrive, Mark Cuban readies to fight Humira's megablockbuster franchise next month, NICE recommends Pfizer's migraine drug for use in the UK, with some restrictions, FDA warns about compounded semaglutide-based drugs, Sanofi rolls out PhII multiple sclerosis data that will take the pharma into pivotal studies next year, MarketingRx roundup: Biogen begins social awareness around postpartum depression; Pharma marketers in the NBA games, Viatris re-ups medical education sponsorship pledge, adds health equity to primary care training, PBM association launches ad campaign pushing back on drugmakers' lobbying power amid congressional pressure, Astellas, Seagen add firefighter messaging in bladder cancer awareness campaign, Genentech sponsors fashion-forward models walking and rolling the runway again in SMA encore show, Gilead adds more patient representation in next phase of HIV med Biktarvy campaign, Novo Nordisk makes the case its more than Wegovy in new corporate ad campaign, Veeva adds generative AI tool for pharma reps as it rolls out new software platform, FDA inspection of China-based site making Coherus' potential new cancer drug ends with three observations, Eli Lilly settles insulin pricing lawsuit for $13.5M, monthly out-of-pocket commitment, EU committee likely to recommend against approving Amylyx ALS drug, company says, FDA lifts hold on Molecular Templates multiple myeloma trial after less than two months, Clinical hold for PepGen's myotonic dystrophy program halts march to the clinic, FDA inspection of UCB facility in Belgium finds several quality issues, A decade in the making: FDA proposes new, easy-to-read patient medication guide, FDA approves Lexicons heart-failure drug after defeat in diabetes, Roche plans to divest from legacy Genentech manufacturing facility in California. Jun 1, 2023 7:08 AM EDT. BioInvent International AB announces it has received Investigational New Drug approval for the monoclonal antibody BI-1910, which will now become its second anti-tumor necrosis factor receptor 2 program to enter clinical development. ARTICLES: Here are the top 15 players, A radioactive prostate cancer therapy is a last lifeline for patients. We expect additional readouts of cancer vaccines in randomized trials that will further inform whether recent advances in antigen targeting, vaccine potency, and patient selection were sufficient to overcome the historical challenges, Daina M. Graybosch, PhD, senior managing director, immuno-oncology, SVB Securities, wrote last summer. Despite newly realized fears of an activist FTC, analysts expect dealmaking to continue this year with small buyouts like Ironwoods acquisition of VectivBio as well as larger M&A. process and share your personal data, including information on your rights The FDA approved Pfizers RSV vaccine called Abrysvo for older adults on Wednesday, placing another Big Pharma onto the commercial stage ahead of the next RSV season. Private equity deal activity in the pharmaceutical industry in The US decreased by 27% in Q1 2023, Communications in life sciences: Uncovering the Unlocked survey results, Medicines adherence: Overcoming pharmas biggest barrier to treatment success, Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective, privacy The daily news briefing from the clinical trials market. The leasing industry's most comprehensive news and information delivered every quarter. Subscribe to our daily newsletter to get the latest news from the world of freight, transportation and logistics. Our Viral Clearance Services team provides fully cGMP-compliant services from research and development assessments through manufacturing, clinical trials, and . Your submission has been received! The trial failure is the second for an ALS medicine this week, adding to a lengthylist of study setbacks that have thinned the pipeline of experimental medicines for the disease in recent years. The process uses a filter material thatcaptures impurities while allowing thenecessarydrug substancesto pass through. WHO Pharmaceuticals Newsletter - N1, 2021 Kite Pharma, a Gilead Sciences company, in December committed up to $4 billion-plus toward co-development of Arcellxs multiple myeloma CAR T-cell therapy CART-ddBCMA. Visit PharmaTimes Media Ltd's profile on Instagram. Eurofins BioPharma Services Newsletter - Eurofins Scientific Biohaven sends latest drug to FDA, despite past trial setback, FDA pauses PepGens plans to test muscle disease drug, Amylyxs ALS drug could face rejection in Europe, Pfizer says hemophilia drug succeeded in Phase 3 study, Akebia says FDA will give its once-rejected anemia pill a second chance, Rain Oncology to cut workforce by 65% after study failure, Serial biotech founder Tim Springer on investing in startups and democratizing antibody research, J&J antibody drug combination shows promise in multiple myeloma, ASCO puts spotlight on advancing antibody-drug conjugate pipeline, Bristol Myers data make case for earlier use of bone marrow disease drug, BenevolentAI CFO resigns as company lays off staff, restructures, Illumina chair loses to Icahn pick as proxy battle ends, Apellis abandons ALS drug after study miss, Annexon claims a silver lining in failed eye drug study, House lawmakers, PBM lobby spar over committee hearing, Digital health funding holds steady in Q1 after year of decline, FDA delays decision on Duchenne gene therapy, considers narrower approval, PTC lays off staff, fires CFO as neuromuscular drug study fails, The latest developments on the gene therapy frontier, Nano Imrad Technology (NIT) Announces Availability Of Actinium-225, Pioneering A New Era Of Ca, Reinforcing Patient Inclusion Through Education: FGK Donates to EUPATI with FindMeCures Tria, DDReg - Delivering Regulatory Excellence since 2009, Digital analytics driving optimum HCP engagement: New survey insights, Big Pharma keeps on coming to Boston: Thats where the action is, FTC Chair Lina Khan Investigation Launched by US House Committee, Biden plans to pick physician Mandy Cohen to lead CDC, Extending Genetic Services Across Clinical Specialties to Improve Proactive Care, Telegenetics and the Changing Needs of Biopharma Clinical Trials.
Nars Red Lizard Discontinued, Articles B